Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 118276-06-5 | MDL No. : | MFCD06797917 |
Formula : | C7H4F2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | SKOYTQILPMNZQO-UHFFFAOYSA-N |
M.W : | 158.10 | Pubchem ID : | 10192584 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 33.77 |
TPSA : | 37.3 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.39 cm/s |
Log Po/w (iLOGP) : | 1.18 |
Log Po/w (XLOGP3) : | 1.23 |
Log Po/w (WLOGP) : | 2.32 |
Log Po/w (MLOGP) : | 1.66 |
Log Po/w (SILICOS-IT) : | 2.35 |
Consensus Log Po/w : | 1.75 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.93 |
Solubility : | 1.85 mg/ml ; 0.0117 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.61 |
Solubility : | 3.87 mg/ml ; 0.0245 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.32 |
Solubility : | 0.764 mg/ml ; 0.00483 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.05 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
58% | Stage #1: for 15 h; Inert atmosphere; Reflux Stage #2: for 0.5 h; Cooling |
This compoundwas preparedbased on the methodology described by Lawrence et al. [29] withsome modifications: 2,6-difluorophenol (0.300 g, 2.3 mmol) and hexamethylenetetramine(0.323 g, 2.3 mmol) were refluxed intrifluoroacetic acid (3.5 mL, 45.7 mmol) for 15 h under argon atmosphere.The product was concentrated, combined with 15 mL of icewater and stirred for 30 min. The resultant mixture was basified withNa2CO3 and extracted with dichloromethane. The aqueous phase wasacidified with HCl (1 mol L−1) and then extracted four times with dichloromethane.The organic fractions were collected, dried withMgSO4 and rotary-evaporated. The product is a cream solid (0.212 g,58percent yield) with a melting point of 116–118 °C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | Reflux | General procedure: A solution of the selected phenol (10 mmol) and hexamethylenetetramine (11 mmol, 1.550 g) in trifluoroacetic acid (10 mL) was stirred and heated at reflux overnight. After cooling to room temperature, the crude product mixture was evaporated under reduced pressure and the yellow residue obtained was poured into distilled water and crushed ice. The cream-colored solid that precipitated was filtered under reduced pressure, washed with distilled water and dried at room temperature under vacuum, yielding the desired compound as a white solid. See, e.g., (Scheme 1, Figure 2). Yield: 60percent, 940 mg; mp (°C): 117-119 (Lit. 116-118, see reference [41j);[N. I. Lawrence, L. A. Hepworth, D. Rennison, A. T. McGown, I. A. Hadfield, Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4, I. Fluor. Chem. 123 (2003) 101-108.j ‘H NMR (400 MHz, CDC13):, ppm = 9.81 (1H, s, CH), 7.49 (2H, d, I = 7.2, ArH), 6.45 (1H, bs, OH); ‘3C NMR (100 MHz, CDC13): , ppm = 189.1, 151.8 (dd, J = 245.3 and 5.2 Hz), 139 (t, J = 16.0 Hz), 128.1 (t, J= 5.9 Hz), 113.2 (dd, J= 14.7 and 6.8 Hz); GC-MS (El): mlz (tR, mm) = 158 (7.69) Mt |
[ 63954-77-8 ]
3,5-Difluoro-2-hydroxybenzaldehyde
Similarity: 0.90
[ 405-05-0 ]
3-Fluoro-4-hydroxybenzaldehyde
Similarity: 0.90
[ 192927-69-8 ]
2,4-Difluoro-3-hydroxybenzaldehyde
Similarity: 0.89
[ 887584-91-0 ]
3,4-Difluoro-5-hydroxybenzaldehyde
Similarity: 0.87
[ 1023290-12-1 ]
3-Fluoro-5-hydroxybenzaldehyde
Similarity: 0.84
[ 63954-77-8 ]
3,5-Difluoro-2-hydroxybenzaldehyde
Similarity: 0.90
[ 405-05-0 ]
3-Fluoro-4-hydroxybenzaldehyde
Similarity: 0.90
[ 192927-69-8 ]
2,4-Difluoro-3-hydroxybenzaldehyde
Similarity: 0.89
[ 887584-91-0 ]
3,4-Difluoro-5-hydroxybenzaldehyde
Similarity: 0.87
[ 1023290-12-1 ]
3-Fluoro-5-hydroxybenzaldehyde
Similarity: 0.84
[ 63954-77-8 ]
3,5-Difluoro-2-hydroxybenzaldehyde
Similarity: 0.90
[ 405-05-0 ]
3-Fluoro-4-hydroxybenzaldehyde
Similarity: 0.90
[ 192927-69-8 ]
2,4-Difluoro-3-hydroxybenzaldehyde
Similarity: 0.89
[ 887584-91-0 ]
3,4-Difluoro-5-hydroxybenzaldehyde
Similarity: 0.87
[ 1023290-12-1 ]
3-Fluoro-5-hydroxybenzaldehyde
Similarity: 0.84